167 related articles for article (PubMed ID: 27099477)
1. Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence.
Chen M; Si L; Winzenberg TM; Gu J; Jiang Q; Palmer AJ
Patient Prefer Adherence; 2016; 10():415-23. PubMed ID: 27099477
[TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence.
You R; Liu Z
Front Pharmacol; 2020; 11():575893. PubMed ID: 33364950
[No Abstract] [Full Text] [Related]
3. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China.
Li N; Zheng B; Liu M; Zhou H; Zhao L; Cai H; Huang J
Menopause; 2019 Aug; 26(8):906-914. PubMed ID: 30994577
[TBL] [Abstract][Full Text] [Related]
5. Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study.
Si L; Winzenberg TM; Chen M; Jiang Q; Neil A; Palmer AJ
Osteoporos Int; 2016 Jul; 27(7):2259-2269. PubMed ID: 26815042
[TBL] [Abstract][Full Text] [Related]
6. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
Hiligsmann M; McGowan B; Bennett K; Barry M; Reginster JY
Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
[TBL] [Abstract][Full Text] [Related]
7. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
Ni W; Jiang Y
Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.
Hiligsmann M; Ben Sedrine W; Reginster JY
J Bone Miner Res; 2013 Apr; 28(4):807-15. PubMed ID: 23165656
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
[TBL] [Abstract][Full Text] [Related]
10. Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.
Yu X; Hao Y; Zhu Z; Zhang W; Liu B; Ma M; Zhang X; Wei N; Wang J; Liu F
Clin Drug Investig; 2023 Apr; 43(4):241-250. PubMed ID: 36929485
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence.
Hiligsmann M; Gathon HJ; Bruyère O; Ethgen O; Rabenda V; Reginster JY
Value Health; 2010; 13(4):394-401. PubMed ID: 20102558
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain.
Darbà J; Pérez-Álvarez N; Kaskens L; Holgado-Pérez S; Racketa J; Rejas J
Clinicoecon Outcomes Res; 2013; 5():327-36. PubMed ID: 23882153
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China.
You R; Liu J; Ke L; Wan M; Zhang Y; Yu G; Mori T
Front Pharmacol; 2022; 13():816248. PubMed ID: 35370751
[No Abstract] [Full Text] [Related]
14. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.
Borgström F; Johnell O; Kanis JA; Oden A; Sykes D; Jönsson B
Pharmacoeconomics; 2004; 22(17):1153-65. PubMed ID: 15612833
[TBL] [Abstract][Full Text] [Related]
15. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Moriwaki K; Mouri M; Hagino H
Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia.
Choo YW; Mohd Tahir NA; Mohamed Said MS; Li SC; Makmor Bakry M
Osteoporos Int; 2022 Sep; 33(9):1909-1923. PubMed ID: 35641572
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea.
Kang JY; Choi L; Johnson B; Yang H
J Bone Metab; 2022 May; 29(2):83-92. PubMed ID: 35718925
[TBL] [Abstract][Full Text] [Related]
19. Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan.
Johnson B; Lai EC; Ou HT; Li H; Stollenwerk B
Arch Osteoporos; 2021 Oct; 16(1):155. PubMed ID: 34636982
[TBL] [Abstract][Full Text] [Related]
20. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
Yoshimura M; Moriwaki K; Noto S; Takiguchi T
Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
